Novel broad spectrum β-lactamase inhibitors

• PHILLIPS OA: β-Lactamase inhibitors: a survey of the patent literature 2000 – 2004. Expert Opin. Ther. Patents (2006) 16(3):319-331.
   Web of Science ®Google Scholar
• GEORGOPAPADAKOU NH: β-Lactamase inhibitors: evolving compounds for evolving resistance targets. Expert Opin. Investig. Drugs (2004) 13(10):1307-1318.
   PubMed Web of Science ®Google Scholar
• BUSH K: The impact of β-lactamases on the development of novel antimicrobial agents. Curr. Opin Investig. Drugs (2002) 3(9):1284-1290.
   PubMedGoogle Scholar
• BUYNAK JD: Understanding the longevity of the β-lactam antibiotics and of antibiotic/β-lactamase inhibitor combinations. Biochem. Pharmacol. (2006) 71(7):930-940.
   PubMed Web of Science ®Google Scholar
• JACOBY GA, MUNOZ-PRICE LS: The new β-lactamases. N. Engl. J. Med. (2005) 352(4):380-391.
   PubMed Web of Science ®Google Scholar
• BUSH K: New β-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin. Infect. Dis. (2001) 32(7):1085-1089.
   PubMed Web of Science ®Google Scholar
• LIVERMORE DM, HAWKEY PM: CTX-M: changing the face of ESBLs in the UK. J. Antimicrob. Chemother. (2005) 56(3):451-454.
   PubMed Web of Science ®Google Scholar
• PATERSON DL, BONOMO RA: Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. (2005) 18(4):657-686.
   PubMed Web of Science ®Google Scholar
• BRADFORD PA: Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. (2001) 14(4):933-951.
   PubMed Web of Science ®Google Scholar
• PAGAN-RODRIGUEZ D, ZHOU X, SIMMONS R et al.: Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 – > Gly SHV-1 β-lactamase: insights intothe mechanism of inhibition. J. Biol. Chem. (2004) 279(19):19494-19501.
   PubMedGoogle Scholar
• PHILIPPON A, ARLET G, JACOBY GA: Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother. (2002) 46(1):1-11.
   PubMed Web of Science ®Google Scholar
• FARMER TH, DEGNAN BA, PAYNE DJ: Penetration of β-lactamase inhibitors into the periplasm of Gram-negative bacteria. FEMS Microbiol. Lett. (1999) 176(1):11-15.
   PubMed Web of Science ®Google Scholar
• DOMENECH-SANCHEZ A, PASCUAL A, SUAREZ AI et al.: Activity of nine antimicrobial agents against clinical isolates of Klebsiella pneumoniae producing extended-spectrum β-lactamases and deficient or not in porins. J. Antimicrob. Chemother. (2000) 46(5):858-860.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-MARTINEZ L, PASCUAL A, HERNANDEZ-ALLES S et al.: Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob. Agents Chemother. (1999) 43(7):1669-1673.
   PubMed Web of Science ®Google Scholar
• LIVERMORE DM: Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1992) 36(9):2046-2048.
   PubMed Web of Science ®Google Scholar
• LI XZ, MA D, LIVERMORE DM, NIKAIDO H: Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to β-lactam resistance. Antimicrob. Agents Chemother. (1994) 38(8):1742-1752.
   PubMed Web of Science ®Google Scholar
• QUALE J, BRATU S, GUPTA J, LANDMAN D: Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. (2006) 50(5):1633-1641.
   PubMed Web of Science ®Google Scholar
• LI X-Z, ZHANG L, SRIKUMAR R, POOLE K: β-Lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1998) 42(2):399-403.
   PubMed Web of Science ®Google Scholar
• LISTER PD, PREVAN AM, SANDERS CC: Importance of β-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam. Antimicrob. Agents Chemother. (1997) 41(4):721-727.
   PubMed Web of Science ®Google Scholar
• COLEMAN K, GRIFFIN DR, PAGE JW, UPSHON PA: In vitro evaluation of BRL 42715, a novel β-lactamase inhibitor. Antimicrob. Agents Chemother. (1989) 33(9):1580-1587.
   PubMed Web of Science ®Google Scholar
• FARMER TH, PAGE JW, PAYNE DJ, KNOWLES DJ: Kinetic and physical studies of β-lactamase inhibition by a novel penem, BRL 42715. Biochem. J. (1994) 303(3):825-830.
   PubMedGoogle Scholar
• COLEMAN K, GRIFFIN DR, UPSHON PA: Pharmacokinetic studies and renal dehydropeptidase stability of the new β-lactamase inhibitor BRL 42715 in animals. Antimicrob. Agents Chemother. (1991) 35(9):1748-1752.
   PubMed Web of Science ®Google Scholar
• BUYNAK JD: The discovery and development of modified penicillin- and cephalosporin-derived β-lactamase inhibitors. Curr. Med. Chem. (2004) 11:1951-1964.
   PubMed Web of Science ®Google Scholar
• ABOU-KHALIL E, BEAULIEU C, BERNSTEIN N et al.: Sulfonamidomethylphosphonates: novel non-β-lactam β-lactamase inhibitors. Interscience Conference Antimicrobial Agents Chemotherapy. Chicago, USA (16 – 19 December 2001).
   Google Scholar
• VENKATESAN AM, AGARWAL A, ABE T et al.: Novel imidazole substituted 6-methylidene-penems as broad-spectrum β-lactamase inhibitors. Bioorg. Med. Chem. (2004) 12(22):5807-5817.
   PubMed Web of Science ®Google Scholar
• VENKATESAN AM, GU Y, SANTOS OD et al.: Structure–activity relationship of 6-methylidene penems bearing tricyclic heterocycles as broad-spectrum β-lactamase inhibitors: crystallographic structures show unexpected binding of 1,4-thiazepine intermediates. J. Med. Chem. (2004) 47(26):6556-6568.
   PubMedGoogle Scholar
• WEISS WJ, PETERSEN PJ, MURPHY TM et al.: In vitro and in vivo activities of novel 6-methylidene penems as β-lactamase inhibitors. Antimicrob. Agents Chemother. (2004) 48(12):4589-4596.
   PubMed Web of Science ®Google Scholar
• BONNEFOY A, DUPUIS-HAMELIN C, STEIER V et al.: In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J. Antimicrob. Chemother. (2004) 54(2):410-417.
   PubMed Web of Science ®Google Scholar
• MIOSSEC C: NXL104: β-Lactamase inhibitor. Challenge of Antibacterial Drug Development. San Diego, USA (21 – 22 March 2007).
   Google Scholar
• BRADFORD PA, BRATU S, URBAN C et al.: Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin. Infect. Dis. (2004) 39(1):55-60.
   PubMed Web of Science ®Google Scholar
• KACZMAREK FM, DIB-HAJJ F, SHANG W, GOOTZ TD: High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of blaACT-1 β-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin PhoE. Antimicrob. Agents Chemother. (2006) 50(10):3396-3406.
   PubMed Web of Science ®Google Scholar
• MENA A, PLASENCIA V, GARCIA L et al.: Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J. Clin. Microbiol. (2006) 44(8):2831-2837.
   PubMed Web of Science ®Google Scholar
• WOZNIAK SE, SHAW RW: In vivo tests of nucleic acid-based metallo-β-lactamase inhibitors in cultures of Bacillus cereus 5/B/6. Experimental Biology Meeting. San Francisco (1 – 5 April 2006). FASEB J. (2006) 20:A897.
   Google Scholar
• AMBLER RP: The structure of β-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci. (1980) 289(1036):321-331.
   PubMed Web of Science ®Google Scholar

Patents

• ALAMX: US6916801 (2005).
   Google Scholar
• RESEARCH CORPORATIONS TECHNOLOGIES: US6906054 (2005).
   Google Scholar
• JD BUYNAK, H CHEN: US7022691 (2006).
   Google Scholar
• METHYLGENE, INC.: US7030103 (2007).
   Google Scholar
• METHYLGENE, INC.: US6921756 (2005).
   Google Scholar
• METHYLGENE, INC.: US7030103 (2006).
   Google Scholar
• METHYLGENE, INC.: US7205285 (2007).
   Google Scholar
• WYETH: US7112582 (2006).
   Google Scholar
• WYETH: US7018997 (2006).
   Google Scholar
• WYETH: US2007/0129344 (2007).
   Google Scholar
• WYETH: US2007/027130 (2007).
   Google Scholar
• AVENTIS PHARMA SA: US7112592 (2006).
   Google Scholar
• BASILEA PHARMACEUTICA AG: WO2007065288 (2007).
   Google Scholar
• TEXAS TECH UNIVERSITY SYSTEM: WO200702016 (2007).
   Google Scholar
• TEXAS TECH UNIVERSITY SYSTEM: WO2006135431 (2006).
   Google Scholar
• SHAW et al.: US2005/0202434 (2005).
   Google Scholar